Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional studyResearch in context

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional studyResearch in context

Summary: Background: The cardiovascular and kidney benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors in people with chronic kidney disease (CKD) are well established. The implementation of updated SGLT2 inhibitor guidelines and prescribing in the real-world CKD population remains large...

Full description

Bibliographic Details
Main Authors: Anna K. Forbes, William Hinton, Michael D. Feher, William Elson, Mark Joy, José M. Ordóñez-Mena, Xuejuan Fan, Nicholas I. Cole, Debasish Banerjee, Rebecca J. Suckling, Simon de Lusignan, Pauline A. Swift
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:EClinicalMedicine
Subjects:
Sodium-glucose transporter 2 inhibitors
Electronic health records
Guideline adherence
Primary health care
Chronic kidney disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024000051

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024000051

Similar Items